{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:20:04Z","timestamp":1768461604220,"version":"3.49.0"},"reference-count":57,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:00:00Z","timestamp":1626739200000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Lab Hematology"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Therapies in myeloma are rapidly advancing with a host of new targeted therapies coming to market. While these drugs offer significant survival benefits and better side\u2010effect profiles compared with conventional chemotherapeutics, they raise significant difficulties in monitoring post\u2010therapy disease status by flow cytometry due to assay interference and\/or selection of phenotypically different sub\u2010clones. The principal culprit, anti\u2010CD38 monoclonal antibodies, limits the ability to detect plasma cells based on classical CD38\/CD45 gating. Other markers, such as CD138, are known to be suboptimal by flow cytometry. Various techniques have been proposed to overcome this problem. The most promising of these techniques has been the marker VS38c, a monoclonal antibody targeting an endoplasmic reticulum protein which has shown high sensitivity for plasma cells. Alternative techniques for gating plasma cells, while variably effective in the near term are already the subject of several targeted therapies rendering their usefulness limited in the longer term. Likewise, future targets of these therapies may render present aberrancy markers ineffective in MRD testing. These therapies pose challenges that must be overcome with new markers and novel panels in order for flow cytometric MRD testing to remain relevant.<\/jats:p>","DOI":"10.1111\/ijlh.13587","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:50:39Z","timestamp":1626828639000},"page":"71-77","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Flow cytometric myeloma measurable residual disease testing in the era of targeted therapies"],"prefix":"10.1111","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8604-2073","authenticated-orcid":false,"given":"David P.","family":"Ng","sequence":"first","affiliation":[{"name":"University of Utah  Salt Lake City UT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,7,20]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1508624"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2008.001628"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1159\/000077554"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.8.2691"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00675.x"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.113"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1746"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.216"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-159624"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.2119"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00377-0"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082322"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8533"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00699"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0057"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0866"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21482"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0205-9"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32065"},{"key":"e_1_2_9_23_1","volume-title":"FDA Approves Isatuximab\u2010irfc for Multiple Myeloma","year":"2020"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01311-1"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21228"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqw052"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21249"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21844"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.29"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21265"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403948"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2014-202421"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3880435"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08203.x"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00623.x"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.06.016"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-555169"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11080"},{"key":"e_1_2_9_39_1","first-page":"221","article-title":"VS38 identifies myeloma cells with dim CD38 expression and plasma cells following daratumumab therapy, which interferes with CD38 detection for 4 to 6 months","volume":"153","author":"Courville EL","year":"2020","journal-title":"Am J Clin Pathol"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.169235"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12902"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21269"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0337-y"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.036814"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01243"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-019-02685-z"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1260419"},{"key":"e_1_2_9_49_1","volume-title":"FDA Granted Accelerated Approval to Belantamab Mafodotin\u2010blmf for Multiple Myeloma","year":"2020"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10948-w"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793869"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.08.018"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07024.x"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404558"},{"key":"e_1_2_9_55_1","unstructured":"ClinicalTrials.gov.A phase I study of Lintuzumab\u2010Ac225 in patients with refractory multiple myeloma. Updated May 20 2020.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02998047. Accessed April 19 2021."},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0818-9"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001079"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190186"}],"container-title":["International Journal of Laboratory Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijlh.13587","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijlh.13587","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijlh.13587","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T04:33:58Z","timestamp":1693283638000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijlh.13587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":57,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1111\/ijlh.13587"],"URL":"https:\/\/doi.org\/10.1111\/ijlh.13587","archive":["Portico"],"relation":{},"ISSN":["1751-5521","1751-553X"],"issn-type":[{"value":"1751-5521","type":"print"},{"value":"1751-553X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"2021-02-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}